Aerosol Science

Dose Uniformity & Emitted Dose Testing

Per-actuation dose and shot-to-shot uniformity testing for MDIs, DPIs, nebulizers, and nasal sprays - consistency data for evaluating inhalation performance.

We use compendial collection trains, controlled flow and actuation, and HPLC / ELISA / qPCR-ddPCR quantitation to document emitted dose, dose uniformity, and sources of variability.

ISO 17025USP <601>USP <1601>FDA MDI / DPI / nasalReviewed 2026-05-15
Request a quoteSubmit a sample

Purpose & when to use

Dose Uniformity and Emitted Dose (DU / ED) testing measures how much active or tracer reaches a defined collection point per actuation and whether delivery remains consistent shot-to-shot and device-to-device. ARE Labs uses compendial collection trains, controlled flow and actuation, and HPLC / ELISA / qPCR-ddPCR quantitation to report per-shot dose and variability metrics aligned to USP <601>, USP <1601>, and FDA MDI / DPI / nasal-spray guidances. DU / ED supports:

  1. Per-actuation emitted dose and dose-uniformity packages for MDIs, DPIs, nebulizers, and nasal sprays — submission-grade datasets aligned to USP <601>, USP <1601>, and FDA MDI / DPI / nasal guidances.
  2. In vitro bioequivalence and comparability packages for predicate and lifecycle changes — dose-uniformity trending and statistical equivalence framing under FDA bioequivalence and ICH Q5E guidance.
  3. Formulation and component-tolerance screening during development — fast shot-to-shot dose checks for valve, pump, nozzle, or excipient changes under FDA development-stage CMC guidance.
  4. Drift investigation across fill level, aging, storage conditions, and device wear — supports stability and shelf-life packages under USP <601> and ICH Q1A framing.
  5. Variability root-cause investigation when emitted dose exceeds spec — pairs with PSD and high-speed imaging under ICH Q9 quality-risk framing to isolate actuation, leakage, or component contributors.

Use DU / ED testing when emitted dose or uniformity is central to the regulatory or commercial question, including submission packages, predicate comparisons, stability programs, and formulation iteration. Results remain tied to controlled actuation, flow, and collection conditions, with documentation prepared for inspection.

Built for inhalation, intranasal, and oral drug delivery

DU / ED testing spans the device classes where per-actuation dose is the central performance attribute — pharmaceutical inhalation and intranasal devices plus oral spray products under a documented quality system.

  • MDIMetered-dose inhalers
  • DPIDry-powder inhalers
  • NebulizerLiquid aerosol generators
  • Nasal sprayIntranasal delivery
  • Oral spraySublingual and topical-oral

Instrumentation & measurement ranges

Platform selection depends on the device class, active, and regulatory frame. Each component is defined during study planning and documented in the report.

1 – 100 L/mininduction-port-flow

Compendial collection trains (USP-aligned fixtures)

USP-aligned induction port, mouthpiece adapters, and nasal / oral interfaces — compliant geometry for emitted-dose collection across MDI, DPI, nebulizer, and nasal-spray devices.

1 – 100 L/mincontrolled-flow

Mass-flow controllers and inhalation profile rigs

Calibrated flow control for steady-state and breathing-simulation profiles — pinned by mass-flow controllers and logged shot-by-shot for traceable per-actuation conditions.

0.1 – 100 Nactuation-force

Stepper-driven actuation fixtures

Controlled stroke, force, and timing under stepper control — manual, pneumatic, or mechanical fixtures sized to mimic patient or operator use across the actuation envelope.

0.1 – 1000 µgper-actuation

Analytical quantitation suite (HPLC, ELISA, qPCR / ddPCR)

HPLC for small-molecule actives, ELISA for protein analytes, and qPCR / ddPCR for nucleic-acid actives — assay matched to the active and matrix on a per-study basis.

Test method options

MethodStrengthsTradeoffAligned with
Compendial-aligned emitted dose and uniformity (USP <601> / <1601>)
  • Submission-grade per-actuation dose and uniformity datasets — the canonical compendial package under USP <601> and USP <1601>.
  • Documented acceptance logic and statistical framing for FDA MDI / DPI / nasal submissions and lifecycle change packages.
Strict fixture, flow, and assay control overhead — best when the device is locked and the data is filing-bound.
USP <601>USP <1601>FDA MDI / DPI / nasal
Development screening for dose consistency
  • Faster iteration with reduced replicates — supports formulation, valve, pump, and component-tolerance screening under FDA development-stage CMC framing.
  • Same fixtures as the compendial method but acceptance bands tuned for iteration speed over filing rigor — design-team-friendly cadence.
May require follow-on confirmation under compendial conditions before filing — bridge to the regulator-aligned method when the program approaches submission.
FDA MDI / DPI / nasal
Robustness study (actuation profile, flow, environment)
  • Surfaces sensitivity to actuation force, flow profile, fill level, and temperature — defines the use-condition envelope where dose stays in spec.
  • Output feeds change-control packages and predicate comparisons under USP <601> and FDA MDI / DPI / nasal change-control framing.
More conditions per study increase sample count and analyst time — scope tightly to the variables that drive the decision.
USP <601>FDA MDI / DPI / nasal
Troubleshooting and root-cause investigation
  • Pinpoints sources of variability — valve, pump, viscosity, leakage, or actuator wear — using paired methods and instrument records.
  • Often paired with PSD or plume geometry under ICH Q9 quality-risk framing so the investigation closes with a defensible CAPA package.
Iterative by nature — schedule unpredictability is higher than fixed-protocol studies; budget for two or three investigation rounds.
ICH Q9

Setup configurations

Study configuration depends on the device, active, and regulatory frame. The setup maintains compendial rigor through controlled flow, repeatable actuation, and traceable collection while accounting for how the device behaves in practice. During study planning, ARE Labs defines the following dimensions for each test program and documents them in advance:

Device interfaces

Mouthpiece adapters, induction ports, nasal and oral interfaces — geometry matched to the device class and the compendial frame under test.

Flow & actuation profiles

Mass-flow-controlled flow profiles, stepper-driven actuation force and stroke, and defined shot schedules — every parameter logged shot-by-shot.

Sample numbers

Replicates per device and across devices — power sized to declared shot-to-shot and device-to-device variability with documented statistical framing.

Media & handling

Collection-media selection, extraction-solvent compatibility, and documented storage for collected fractions and analytical samples.

Calibration & verification

Mass-flow controllers, actuation force, and assay calibration verified against traceable standards before each campaign and between condition blocks.

Methods anchored to the standards that matter

Each DU / ED study operates within a documented quality system aligned with regulatory frames for inhalation, intranasal, and oral-spray products. The four anchors below establish the quality and documentation requirements carried through to the §7 outputs.

  • ISO 17025AccreditedTesting-laboratory competence — documented methods, calibration traceability, and uncertainty contributors.
  • USP <601>AccreditedAerosols, nasal sprays, MDIs, and DPIs — performance quality tests including delivered-dose uniformity.
  • USP <1601>AlignedProducts for nebulization — characterization tests including aerosol output and dose.
  • FDA MDI / DPI / nasalAlignedChemistry, manufacturing, and controls plus bioequivalence framing for inhalation and intranasal submissions.

Key data outputs & reporting

DU / ED reports pair the per-actuation results with uniformity statistics and the supporting datasets. Standard outputs include emitted dose per shot; summary statistics such as mean, SD, and CV; dose-vs-shot trends where applicable; and traceable QA / QC controls. ARE Labs formats the reports and data files for submission packages, change-control documentation, or development decisions. Comparability programs, predicate studies, and stability time-courses receive the additional artifacts listed beneath the table.

Primary outputs

  • Emitted dose per actuation and summary statistics across shots, devices, and lots (mean, SD, CV, condition deltas).
  • Dose-uniformity trending across shot number, fill level, or canister-life position with predefined acceptance bands.
  • Assay calibration, recovery, and uncertainty contributors documented alongside results for inspection-readiness.

Deliverables

#FormatContents
01PDF reportMethods, controls, statistical framing, and acceptance logic.
02CSV / XLSX datasetsPer-shot dose, replicate statistics, and condition deltas.
03FiguresDose-vs-shot plots, condition overlays, and distribution charts for internal review and submission appendices.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Comparability appendix — Side-by-side dose-vs-shot overlays plus statistical equivalence tests per ICH Q1E or product-specific predicate framing.
  • Stability time-course pack — Emitted-dose and uniformity trends across timepoints with predefined OOT criteria flagged per ICH Q1A.
  • Method-development notes — Fixture, actuation, and assay-selection rationale plus uncertainty contributors — for submission cover letters and inspection readiness.

QA / QC & data integrity

Each study includes a documented QA / QC framework sized to the method plan. ARE Labs selects controls and verifications based on the regulatory frame, analytical chemistry, and decision the data will support. These checks run alongside dose collection, are audited under our ISO 17025 quality system, and remain traceable from sample receipt through the final result. Recovery, system suitability, and matrix-effect checks are added when the assay requires them.

Blanks and background controls for collection media plus fixture-residue checks before each campaign.

Replicate measurements and repeat runs to quantify shot-to-shot and device-to-device precision.

Assay controls — calibration standards, system suitability per assay, and spike-recovery on matrix-challenging analytes.

Flow and actuation verification logs alongside captured doses with mass-flow controller calibration records.

Chain of custody from sample receipt through analysis and final reporting.

RESEARCH / THIS WORK IN PRACTICE

Real studies. Measured evidence.

Explore published studies connected to dose uniformity and emitted dose. Each explains the study question, approach and findings.

View related studies (1)
Inhalation & Drug Delivery

Dry-Powder Nasal Spray Testing: Phase 1 Characterization

The study established an early performance baseline for comparing the two variants and provided data for a regulatory-facing Phase 1 characterization package. It did not assess clinical efficacy or support claims of approval.

Selected finding
Recovered material was predominantly classified in the nasal or upper-airway region for both variants.
Nasal deliveryParticle sizingDevice evaluation

Study-specific findings do not guarantee performance for another product.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

When scoping dose uniformity or emitted dose testing, inhalation, intranasal, and oral-spray teams often ask about assay selection, fixture choice, replicate plans, comparability framing, and deliverables. The answers below provide practical starting points, not protocols. Device design, active, and regulatory frame still shape the final setup, and most DU / ED studies require at least one custom configuration choice. ARE Labs confirms those details during study planning.

Q.Is emitted dose the same as delivered dose?
A.Emitted dose is the material collected at the device outlet using a defined compendial fixture. Delivered dose may require anatomical models, breathing simulations, or in vivo work. ARE Labs defines the appropriate collection point during study planning.
Q.Can you quantify biologics or nucleic-acid actives?
A.Yes. ARE Labs uses ELISA for protein analytes and qPCR / ddPCR for nucleic-acid actives. Assay controls, system suitability, and recovery are documented with the results. The collection fixtures remain compendial, while the assay is matched to the active.
Q.How many actuations should be tested?
A.The appropriate number depends on device output, assay sensitivity, and the comparability target. Submission packages typically use n=10+ devices with replicates across canister positions, while development screening uses fewer. ARE Labs defines shot counts during study setup.
Q.What drives dose variability most often?
A.Common contributors include actuation force and timing, component tolerances (valve, pump, nozzle), leakage, and formulation viscosity. We control flow and actuation, log each shot, and document assay recovery so the resulting comparison remains interpretable.
Q.What do you deliver?
A.Deliverables include a PDF report covering methods, controls, statistical framing, and acceptance logic. CSV / XLSX datasets contain per-shot dose and replicate statistics. Figures include dose-vs-shot plots, condition overlays, and distributions for internal review or submission appendices.

Standards & guidance

ARE Labs conducts DU / ED studies in alignment with the regulatory and consensus standards governing inhalation, intranasal, and oral-spray dose delivery. Methods within our third-party accreditation scope are documented as accredited (ISO 17025, USP <601>). When ARE Labs follows a standard outside that formal scope, the method is described as aligned or conformant where applicable. The cards below identify the standards most often relevant to DU / ED packages.

Inhalation & Drug Delivery - Accredited

USP <601>

Aerosols, nasal sprays, MDIs, and DPIs — performance quality tests including delivered-dose uniformityView standard ->Inhalation & Drug Delivery - Aligned

USP <1601>

Products for nebulization — characterization tests including aerosol output and doseView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Chemistry, manufacturing, controls, and bioequivalence framing for inhalation and intranasal submissionsView standard ->QA & Regulatory - Aligned

ICH Q9

Quality risk management — investigation framing for dose-variability root-cause workView standard ->

Related services & devices

Service

Particle Size Distribution (PSD) Testing

Pairs with DU / ED for inhalation submissions — size-fraction data complementing per-actuation dose for the full performance package.Read more ->Devices

Respiratory Drug Delivery Devices

MDI, DPI, and nebulizer programs — emitted dose, uniformity, and submission-grade characterization across the device portfolio.Read more ->Service

Spray Pattern & Plume Geometry

Pairs with DU / ED for nasal-spray submissions — plume metrics that contextualize per-actuation dose against device geometry.Read more ->Devices

Intranasal Delivery Devices

Nasal pumps, multi-dose sprays, and unit-dose devices — per-actuation dose plus comparability characterization for nasal submissions.Read more ->